Related Experiment Video

Updated: Jun 4, 2026

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats
07:56

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Published on: April 21, 2017

Paediatric stroke: genetic insights into disease mechanisms and treatment targets

Pinki Munot1, Yanick J Crow, Vijeya Ganesan

  • 1Department of Neurology, Great Ormond Street Hospital for Children NHS Trust, London, UK. munotp@gosh.nhs.uk

The Lancet. Neurology
|February 26, 2011
PubMed

Insights

Childhood stroke, a significant cause of death and disability, requires tailored treatments. Understanding the genetic basis of childhood arterial ischemic stroke can reveal new therapeutic targets and repurpose existing drugs.

Area of Science:

  • Pediatric Neurology
  • Vascular Biology
  • Genetics

Background:

  • Childhood stroke presents significant mortality and long-term morbidity, with high recurrence rates.
  • Current treatment guidelines for pediatric stroke rely on adult data, lacking specific efficacy in children.
  • Risk factors and disease mechanisms in childhood stroke differ from adult stroke.

Purpose of the Study:

  • To explore the pathogenesis of childhood arterial ischemic stroke (AIS) and cerebral arteriopathy.
  • To investigate insights from Mendelian diseases associated with increased risk of childhood AIS.
  • To identify novel therapeutic targets and potential drug repurposing opportunities for pediatric stroke.

Main Methods:

  • Review of current knowledge on Mendelian diseases linked to childhood stroke.
  • Analysis of genetic and molecular insights into vascular development and homeostasis.
  • Examination of the response to environmental effects in the context of stroke pathogenesis.

Main Results:

  • Mendelian diseases offer crucial insights into the pathogenesis of childhood AIS and cerebral arteriopathy.
  • Understanding genetic underpinnings can illuminate specific disease mechanisms.
  • Specific genetic pathways involved in vascular development and response to environmental factors are implicated.

Conclusions:

  • Insights from Mendelian diseases can guide the development of targeted treatments for childhood stroke.
  • Existing pharmaceuticals may be repurposed for pediatric stroke treatment.
  • Further research into genetic factors and disease mechanisms is warranted to improve outcomes for children with stroke.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.